Cellular Dynamics Announces Launch of iCell® Hepatoblasts to Enable Research into Therapies That Stimulate Liver Regeneration

September 22, 2016 – (CDI) – “Cellular Dynamics International, Inc. (CDI), a FUJIFILM company, today announced the launch of iCell® Hepatoblasts, liver progenitor cells generated from human induced pluripotent stem cells (iPSCs). These cells show promise for liver regeneration therapy research by enabling researchers to identify molecules […]

Read more

Rare, Life-Threatening Childhood Disease is the Focus of CIRM’s Most Recent Investment

September 21, 2016 – (CIRM) – “Cystinosis is a rare disease that usually strikes children before they are two years old and can lead to end stage kidney failure before their tenth birthday. Current treatments are limited, which is why the CIRM Board today approved $5.2 million […]

Read more

Investment in the cell and gene therapy industry in the UK grows 10x since 2012 to £400m/year

September 21, 2016 – (Catapult) – “The Cell and Gene Therapy Catapult (CGT Catapult) today published its Annual Review 2015/16 which included statistics on UK industry growth. The Review is being launched at the inaugural UK Regenerative Medicine Conference in London hosted jointly by the CGT Catapult […]

Read more

Capricor Therapeutics Announces Closing of Public Offerings Raising Approximately $10.0 Million in Net Proceeds

September 21, 2016 – (Capricor) – “Capricor Therapeutics, Inc. today announced the closing of its previously announced underwritten registered public offering and concurrent registered direct offering. In the registered public offering, a total of 3,090,625 shares of the Company’s common stock were sold at an offering price […]

Read more

Kite Pharma Announces Exclusive License with the National Institutes of Health for Multiple Neoantigen Directed T-Cell Receptor (TCR) Product Candidates to Treat Solid Tumors Expressing Mutated KRAS

September 20, 2016 – (Kite) – “Kite Pharma, Inc., a clinical-stage biopharmaceutical company focused on developing engineered autologous T-cell therapy (eACT™) products for the treatment of cancer, today announced that the Company has entered into an exclusive, worldwide license with the National Institutes of Health (NIH) for […]

Read more

Caladrius Subsidiary, PCT, Announces Five-Year Strategic Manufacturing Services Agreement with Adaptimmune

September 19, 2016 – (Caladrius) – “Caladrius Biosciences, Inc. (“Caladrius” or the “Company”), a cell therapy company combining an industry-leading development and manufacturing services provider (PCT, LLC, A Caladrius Company or “PCT”) with a select therapeutic development pipeline, today announces a new five-year strategic manufacturing services agreement […]

Read more

Histogenics Corporation Announces $30.0 Million Private Placement

September 16, 2016 – (Histogenics) – “Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that it has entered into a definitive securities purchase agreement to raise approximately $30.0 million in a private placement of common […]

Read more

Caladrius Biosciences, Inc. Enters Into Agreements To Raise $25 Million in Common Equity Priced At Market Without Warrants

September 15, 2016 – (Caladrius) – “Caladrius Biosciences, Inc. (“Caladrius” or the “Company”), a cell therapy company combining an industry-leading development and manufacturing services provider through its subsidiary PCT, LLC a Caladrius Company™ (“PCT”) with a select therapeutic development pipeline, today announced that on September 14, 2016, […]

Read more

RepliCel Life Sciences Announces Non-Brokered Private Placement

September 14, 2016 – (RepliCel) – “RepliCel Life Sciences Inc. (“RepliCel” or the “Company”), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today it intends to undertake a non-brokered private placement financing, on a commercially reasonable basis, of up to […]

Read more

SEMMA THERAPEUTICS ANNOUNCES $5 MILLION GRANT FROM CALIFORNIA INSTITUTE OF REGENERATIVE MEDICINE (CIRM) TO DEVELOP NOVEL STEM-CELL DERIVED TREATMENT FOR DIABETES

September 12, 2016 – (Semma) – “Semma Therapeutics, a biopharmaceutical company developing cellular therapy for diabetes, announced today that it has accepted a $5 million grant from the California Institute of Regenerative Medicine (CIRM). The award provides funding to develop personalized cell therapy for the treatment of […]

Read more
Page 1 of 7612345...102030...Last »